布地奈德联合复方异丙托溴铵雾化吸入治疗小儿毛细支气管炎的临床评价

Clinical Evaluation of Budesonide Plus Compound Ipratropium Bromide Aerosol Inhalation in the Treatment of Bronchiolitis in Children

目的评价布地奈德联合复方异丙托溴铵雾化吸入治疗小儿毛细支气管炎的临床疗效及安全性,为临床医师选择合理用药方案提供参考。方法选取本院在2017年12月至2019年2月收治的70例小儿毛细支气管炎患儿为研究对象,采用计算机随机分组法将其分为对照组和观察组,每组各35例。对照组采用布地奈德雾化吸入治疗,观察组采用布地奈德联合复方异丙托溴铵雾化吸入治疗,收集两组患儿的临床症状及体征改善时间、临床疗效、不良反应。结果临床症状、体征改善时间相较于对照组,观察组较短,统计学有意义(P<0.05);临床疗效相较于对照组,观察组较高,统计学有意义(P<0.05);两组不良反应发生率相比,差异不具有统计学意义。结论布地奈德联合复方异丙托溴铵雾化吸入治疗小儿毛细支气管炎,不仅可以使临床症状、体征迅速改善,继而缩短患儿住院时间,而且没有出现严重不良反应,用药安全性较高。

Objective o evaluate the clinical efficacy and safety of budesonide plus compound ipratropium bromide aerosol inhalation in the treatment of infantile bronchiolitis,and to provide reference for clinicians to choose rational drug use.Methods Seventy cases with bronchiolitis in children admitted to Lingyuan Central Hospital from December 2017 to February 2019 were selected as the research objects.They were randomly divided into control group and observation group(35 cases in each group).The control group was treated with budesonide aerosol inhalation,while the observation group was treated with budesonide+compound ipratropium bromide aerosol inhalation.The improvement time of clinical signs,clinical efficacy and adverse reactions were compared between the two groups.Results Compared with the control group,the improvement time of clinical signs was shorter in the observation group,which had statistical significance(P<0.05);the serum level was lower in the observation group than in the control group,which had statistical significance(P<0.05);the clinical effect was higher in the observation group than in the control group,which had statistical significance(P<0.05);the incidence of adverse reactions in the two groups had no statistical significance(P>0.05).Conclusion Budesonide+compound ipratropium bromide aerosol inhalation can not only improve clinical signs and serum levels,but also improve clinical efficacy,and there are no serious adverse reactions.